Crystagen

updated

Crystagen is a trade name that the Khavinson group of Russian short-peptide bioregulators links to the tripeptide Glu-Asp-Pro, sold for sleep and anti-aging and stacked with pinealon and epitalon. No human study exists, and the only paper that names it is one 2014 Russian-language abstract on B-cell activation in the spleen of aging animals, with no species, dose or route stated. The group's own table calls it an immunoprotector and gives the pineal and neuroprotector roles to other peptides.

Synthetic tripeptide bioregulator

  • PubChem has no record under the name Crystagen. The group's 2022 table lists Crystagen (EDP), and the tripeptide Glu-Asp-Pro with all L residues is PubChem CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number.
  • The only paper that names Crystagen is a 2014 Russian-language abstract: it activated B-cells in the spleen of aging animals but did not cause cell renewal, with no species, dose or route stated.
  • The group's table lists Crystagen as an immunoprotector, Pinealon as a neuroprotector, and Epitalon as a geroprotector and regulator of pineal functions, so the sleep claim does not match the group's own classification.
  • The group's laboratory code T-36 is the Glu-Asp-Pro peptide, but no abstract states that T-36 is Crystagen.
  • A PubMed search on 10 October 2026 for crystagen or crystagene returned 1 record, and the same search with sleep, circadian or aging terms returned that same record.
  • A PubMed search for crystagen or Glu-Asp-Pro restricted to clinical trial or randomized controlled trial publication types returned 0 records.

What is Crystagen, and is it an approved drug?

Crystagen is a trade name that the Khavinson group's 2022 table links to the tripeptide Glu-Asp-Pro (EDP), and the table lists it as an immunoprotector. PubChem has no record under the name. ClinicalTrials.gov returned no study, and openFDA Drugs@FDA and DailyMed return no product under the name, so no FDA record was found.

A PubChem name search for Crystagen returned no record. The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. The tripeptide Glu-Asp-Pro with all L residues is PubChem CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number and no Crystagen synonym, so the trade name and the sequence are linked by the group's table only. A PubChem name lookup for Glu-Asp-Pro returns a different record, CID 145455337, whose name carries a (2R) proline center, so the lookup alone gives the wrong stereoisomer.

A 2012 abstract from the group lists synthesized tripeptides under laboratory codes, among them T-36 for Glu-Asp-Pro. T-36 is the same sequence, but the abstract does not use the name Crystagen, so no abstract ties T-36 to Crystagen.

On 10 October 2026 ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed returned no product under the name, so no FDA record was found. That covers FDA and registry sources only and says nothing about other regulators. Whether products outside this field share the name Crystagen was not searched.

PubChem: Glu-Asp-Pro identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 23624313.

A PubChem name search for Crystagen returned no record. The tripeptide Glu-Asp-Pro with all L residues is CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number and no Crystagen synonym. A PubChem name lookup for Glu-Asp-Pro returns a different record, CID 145455337, whose name carries a (2R) proline center, so the lookup alone gives the wrong stereoisomer. The trade name and the sequence are linked by the group's 2022 table only.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence only. The link from the name Crystagen to the sequence rests on the group's own table.

Read the original source
2022 table: Crystagen immunoprotector, Pinealon neuroprotector, Epitalon geroprotector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. It lists Pinealon (EDR) as a neuroprotector and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

The only source that links the trade name Crystagen to the Glu-Asp-Pro sequence. The stack of Crystagen with pinealon and epitalon combines a spleen immune peptide with two peptides from other programs.

Read the original source
2012 skin explants: T-36 (Glu-Asp-Pro) in young and old rat tissue

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro), and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all but T-34 stimulated cell proliferation; in explants from old rats only T-38 had a marked effect. The abstract does not use the name Crystagen, so T-36 is the Glu-Asp-Pro peptide but is not stated to be Crystagen.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, cell proliferation and p53 expression endpoints
Funding
not stated in the source

Sequence-level result under a laboratory code. No abstract ties T-36 to the name Crystagen.

Read the original source
PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

What did the spleen and skin tissue studies find?

The only paper that names Crystagen is a 2014 Russian-language abstract: it activated B-cells in the spleen of aging animals but did not cause cell renewal, with no species, dose or route stated. Under its laboratory code T-36, the Glu-Asp-Pro peptide stimulated proliferation in skin explants from young rats but had no marked effect in explants from old rats. No study measured sleep, lifespan or any clinical outcome.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route or group size. This is an immune-cell result in an aging organ.

A 2012 abstract tested synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp) in organotypic skin explants from rats. In explants from young rats all but T-34 stimulated cell proliferation, and in explants from old rats only T-38 had a marked effect. T-36 is the Glu-Asp-Pro peptide, but the abstract does not state that it is Crystagen, so this is a sequence-level result and not a result under the name.

Neither study measures sleep, lifespan or any clinical outcome. A PubMed search on 10 October 2026 for crystagen or crystagene returned 1 record, the 2014 spleen abstract.

2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
2012 skin explants: T-36 (Glu-Asp-Pro) in young and old rat tissue

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro), and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all but T-34 stimulated cell proliferation; in explants from old rats only T-38 had a marked effect. The abstract does not use the name Crystagen, so T-36 is the Glu-Asp-Pro peptide but is not stated to be Crystagen.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, cell proliferation and p53 expression endpoints
Funding
not stated in the source

Sequence-level result under a laboratory code. No abstract ties T-36 to the name Crystagen.

Read the original source
PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Has Crystagen been tested in people?

No. A PubMed search on 10 October 2026 for crystagen or Glu-Asp-Pro restricted to clinical trial or randomized controlled trial publication types returned 0 records, and ClinicalTrials.gov returned no study for Crystagen. The searches found no human dose and no human safety data.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records.

ClinicalTrials.gov returned no study for Crystagen. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose and no human safety data.

PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Does Crystagen help sleep or aging, alone or stacked with pinealon and epitalon?

No record supports the sleep claim, and the group's own table calls Crystagen an immunoprotector and gives the pineal and neuroprotector roles to epitalon and pinealon. The anti-aging claim rests on B-cell activation without cell renewal in aged spleen tissue, in one abstract with no species or dose, and no study combined Crystagen with pinealon or epitalon.

Sellers promote Crystagen for sleep and anti-aging, stacked with pinealon and epitalon. A PubMed search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned only the 2014 spleen abstract, which measures no sleep and no lifespan.

The group's 2022 table lists Crystagen (EDP) as an immunoprotector, Pinealon (EDR) as a neuroprotector, and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen. The stack combines a spleen immune peptide with two peptides from other programs.

The anti-aging claim has only the observation that B-cells were activated in aged spleen tissue, with no cell renewal, in one abstract that states no species or dose. No study combined Crystagen with pinealon or epitalon.

Every result on this page is for the synthetic tripeptide or its laboratory code. Tissue-extract products sold under similar names are different things, and no PubMed record describes a Cytomax or Cytogen retail product, so nothing here is cited to those product lines.

PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
2022 table: Crystagen immunoprotector, Pinealon neuroprotector, Epitalon geroprotector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. It lists Pinealon (EDR) as a neuroprotector and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

The only source that links the trade name Crystagen to the Glu-Asp-Pro sequence. The stack of Crystagen with pinealon and epitalon combines a spleen immune peptide with two peptides from other programs.

Read the original source

How is Crystagen thought to work?

No mechanism is established. One abstract reports B-cell activation without cell renewal in the spleen of aging animals, and the group's table describes Crystagen as an immunoprotector. No pharmacokinetic data exist.

The only mechanism-level observation under the name is the 2014 spleen abstract: Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose or route, so it does not show how or where the peptide acts.

The group's 2022 table assigns Crystagen the immunoprotector label. No study traces a pathway from that label to sleep or aging, and no pharmacokinetic data were found in any species.

2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
2022 table: Crystagen immunoprotector, Pinealon neuroprotector, Epitalon geroprotector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. It lists Pinealon (EDR) as a neuroprotector and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

The only source that links the trade name Crystagen to the Glu-Asp-Pro sequence. The stack of Crystagen with pinealon and epitalon combines a spleen immune peptide with two peptides from other programs.

Read the original source

What is known about the safety of Crystagen?

No human safety data exist for Crystagen: the searches found no human dose and no human study of any design. The one abstract that names it gives no species, dose or route, so animal safety is not described either, and the trade name is tied to its sequence only by the group's table.

A PubMed search on 10 October 2026 found no clinical trial of Crystagen, and ClinicalTrials.gov returned no study, so there is no human dose and no human safety data.

The 2014 spleen abstract states no species, dose, route or group size. The link between the name and Glu-Asp-Pro rests on the group's table, and a PubChem lookup by the sequence name returns a different stereoisomer, so a record found by sequence needs its stereochemistry confirmed before it is attributed to the peptide.

PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
PubChem: Glu-Asp-Pro identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 23624313.

A PubChem name search for Crystagen returned no record. The tripeptide Glu-Asp-Pro with all L residues is CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number and no Crystagen synonym. A PubChem name lookup for Glu-Asp-Pro returns a different record, CID 145455337, whose name carries a (2R) proline center, so the lookup alone gives the wrong stereoisomer. The trade name and the sequence are linked by the group's 2022 table only.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence only. The link from the name Crystagen to the sequence rests on the group's own table.

Read the original source

Why does Crystagen sit in D tier?

One Russian-language abstract with no stated species, a name tied to its sequence only by the group's table, and a sleep claim that runs against that table's immunoprotector label put Crystagen in D tier. No study measured sleep, lifespan, a combination with pinealon or epitalon, or any human outcome.

Crystagen has a single paper under its name, a Russian-language abstract with no species, dose or route, and an identity link to its sequence that comes only from the group's review table. The sleep claim runs against that table, which calls the peptide an immunoprotector.

A PubMed search on 10 October 2026 found no clinical trial and no study of sleep, and nothing was found on a combination with pinealon or epitalon.

2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
2022 table: Crystagen immunoprotector, Pinealon neuroprotector, Epitalon geroprotector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. It lists Pinealon (EDR) as a neuroprotector and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

The only source that links the trade name Crystagen to the Glu-Asp-Pro sequence. The stack of Crystagen with pinealon and epitalon combines a spleen immune peptide with two peptides from other programs.

Read the original source
PubChem: Glu-Asp-Pro identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 23624313.

A PubChem name search for Crystagen returned no record. The tripeptide Glu-Asp-Pro with all L residues is CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number and no Crystagen synonym. A PubChem name lookup for Glu-Asp-Pro returns a different record, CID 145455337, whose name carries a (2R) proline center, so the lookup alone gives the wrong stereoisomer. The trade name and the sequence are linked by the group's 2022 table only.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence only. The link from the name Crystagen to the sequence rests on the group's own table.

Read the original source
PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Studies and sources

PubChem: Glu-Asp-Pro identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 23624313.

A PubChem name search for Crystagen returned no record. The tripeptide Glu-Asp-Pro with all L residues is CID 23624313, C14H21N3O8, molecular weight 359.33, with no CAS number and no Crystagen synonym. A PubChem name lookup for Glu-Asp-Pro returns a different record, CID 145455337, whose name carries a (2R) proline center, so the lookup alone gives the wrong stereoisomer. The trade name and the sequence are linked by the group's 2022 table only.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence only. The link from the name Crystagen to the sequence rests on the group's own table.

Read the original source
2022 table: Crystagen immunoprotector, Pinealon neuroprotector, Epitalon geroprotector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector and cites a US patent. It lists Pinealon (EDR) as a neuroprotector and Epitalon (AEDG) as a geroprotector, regulator of the epiphysis (pineal) functions, and neuroprotector. A sleep or pineal role belongs to the group's description of epitalon and pinealon, not to Crystagen.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

The only source that links the trade name Crystagen to the Glu-Asp-Pro sequence. The stack of Crystagen with pinealon and epitalon combines a spleen immune peptide with two peptides from other programs.

Read the original source
2012 skin explants: T-36 (Glu-Asp-Pro) in young and old rat tissue

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro), and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all but T-34 stimulated cell proliferation; in explants from old rats only T-38 had a marked effect. The abstract does not use the name Crystagen, so T-36 is the Glu-Asp-Pro peptide but is not stated to be Crystagen.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, cell proliferation and p53 expression endpoints
Funding
not stated in the source

Sequence-level result under a laboratory code. No abstract ties T-36 to the name Crystagen.

Read the original source
2014 abstract: Crystagen activated B-cells in aging spleen, no cell renewal

Animal study

Сhervyakova NA et al. Adv Gerontol. 2014;27(1):224-228. PMID 28976144.

A 2014 Russian-language abstract says Vilon, Timogen, Crystagen, and R-1 short peptides have different immunoprotective effects in the spleen during ageing. Crystagen activated B-cells but did not cause cell renewal in the spleen as it ages. The abstract states no species, dose, route, or group size. This is an immune-cell result in an aging organ; it measures no sleep, no lifespan, and no clinical outcome.

Participants / model
Spleen tissue from aging animals, species not stated in the abstract
Treatment
not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical immune-cell study, Russian-language abstract
Funding
not stated in the source

The only paper that names Crystagen. It gives no species, dose, route or group size.

Read the original source
PubMed: 1 record, no sleep study, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: crystagen[tiab] OR crystagene[tiab]; crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging); (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]). ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for crystagen[tiab] OR crystagene[tiab] returned 1 record, the 2014 spleen abstract. A search for crystagen AND (sleep OR insomnia OR circadian OR melatonin OR aging) returned the same single record. A search for (crystagen OR "Glu-Asp-Pro") AND (clinical trial[pt] OR randomized controlled trial[pt]) returned 0 records. ClinicalTrials.gov returned no study for Crystagen, and openFDA Drugs@FDA and DailyMed return no product under the name. In the records reviewed there is no study of Crystagen on sleep, no study combining it with pinealon or epitalon, no lifespan or anti-aging outcome, no human dose, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Why is Crystagen in D tier?

D fits a compound with one abstract under its name, no stated species, dose or route, and a trade name tied to its sequence only by the group's own table. The sleep claim runs against that table, which calls the peptide an immunoprotector, and no study tested sleep, aging, a combination with other peptides, or any person.